<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467256</url>
  </required_header>
  <id_info>
    <org_study_id>NCPHOI-2018-01</org_study_id>
    <nct_id>NCT03467256</nct_id>
  </id_info>
  <brief_title>CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL</brief_title>
  <official_title>A Single-Arm Phase I/II Study Evaluating the Safety and Clinical Efficacy Of the 2-nd Generation CD19 Autologous CAR T Cells on the CliniMACS Prodigy Automated Manufacturing Platform in Treatment of Paediatric And Young Adult Patients With Relapsed/Refractory B-lineage Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficiency of autologous CD19 CAR-T&#xD;
      lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory&#xD;
      B-lineage acute lymphoblastic leukemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objectives of the study are:&#xD;
&#xD;
        1. To investigate the safety of auto-CD19 CAR T-cells therapy among children and young&#xD;
           adults with refractory/relapsed B-cell ALL on the basis of prospective evaluation of&#xD;
           adverse affects frequency and severity according to CTCAE v.4&#xD;
&#xD;
        2. To study the efficacy of auto-CD19 CAR T-cells therapy among children and young adults&#xD;
           with refractory/relapsed B-cell ALL on the basis of proportion of patients in&#xD;
           haematological and molecular remission at 28 days after infusion.&#xD;
&#xD;
        3. To evaluate long-term efficacy of auto-CD19 CAR T-cells therapy among children and young&#xD;
           adults with refractory/relapsed B-cell ALL on the basis of overall and event-free&#xD;
           survival at 1 and 3 years after infusion.&#xD;
&#xD;
      The novelty of this study will be cytokine release syndrome prophylaxis by tocilizumab&#xD;
      Patients will receive fludarabine 120 mg/m2 (totally) intravenously (IV) over 30 minutes on&#xD;
      days -5 to -2 and cyclophosphamide 750 mg/m2 IV over 60 minutes on day -2. One hour prior to&#xD;
      infusion of CAR T-cells patients will receive tocilizumab IV 8 mg/kg (max 800 mg) over 1&#xD;
      hour. Patients then receive CD19-CAR T cells IV over 20-30 minutes on day 0.&#xD;
&#xD;
      This is a dose-escalation study of CD19-CAR T cells. Dose escalation consistently:&#xD;
&#xD;
        -  Level 1 5х105/kg CD19 CAR-T lymphocytes&#xD;
&#xD;
        -  Level 2 1х106/kg CD19 CAR-T lymphocytes&#xD;
&#xD;
        -  Level 3 3х106/kg CD19 CAR-T lymphocytes&#xD;
&#xD;
        -  Level 0 1х105/kg CD19 CAR-T lymphocytes (in case of dose-limiting toxicity at dose Level&#xD;
           1) In case of severe side affects next dose will be reduced to the previous lower dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 14, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Actual">October 15, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade 3-5 SAE occurring within 30 days of CD19CAR T-cell infusion</measure>
    <time_frame>1 month</time_frame>
    <description>incidence of grade 3-5 SAE according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 occurring within 30 days of CD19CAR T-cell infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade 3-4 Severe Cytokine Release Syndrome following CD19 CAR T-cell infusion</measure>
    <time_frame>1 month</time_frame>
    <description>incidence of grade 3-4 Severe Cytokine Release Syndrome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade 3-5 neurotoxicity occurring within 30 days of CD19 CAR T-cell infusion</measure>
    <time_frame>1 month</time_frame>
    <description>incidence of grade 3-5 neurotoxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 occurring within 30 days of CD19 CAR T-cell infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients in MRD-negative remission</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of patients in MRD-negative remission among all enrolled patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients in hematologic remission</measure>
    <time_frame>1 months</time_frame>
    <description>Proportion of patients in hematologic remission among all patients with morphological disease (NO CR) at enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of MRD-negative remission</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of MRD-negative remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence/frequency of CD19 CAR T lymphocytes in peripheral (FC+qPCR)</measure>
    <time_frame>2 years</time_frame>
    <description>Persistence/frequency of CD19 CAR T lymphocytes in peripheral (FC+qPCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of B-cell aplasia</measure>
    <time_frame>5 years</time_frame>
    <description>Duration of B-cell aplasia and hypogammaglobulinemia, time 0 - day of CD19-CAR T cells infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>the probability of survival, time 0 - day of CD19-CAR T cells infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia, Pediatric</condition>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive fludarabine 120 mg/m2 (totally) intravenously (IV) over 30 minutes on days -5 to -2 and cyclophosphamide 750 mg/m2 IV over 60 minutes on day -2. One hour prior to infusion of CAR T-cells patients will receive tocilizumab IV 8 mg/kg (max 800 mg) over 1 hour. Patients then receive CD19-CAR T cells IV over 20-30 minutes on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Chimeric Antigen Receptor T-Cell Therapy</intervention_name>
    <description>anti-CD19 chimeric antigen receptor - transduced T-cell given IV</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>given IV</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>given IV</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>given IV</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to give informed consent (for patients &gt; 14 years old). For subjects &lt; 18&#xD;
             years old their legal guardian must give informed consent&#xD;
&#xD;
          -  Patients with relapsed or refractory CD19-expressing B cell ALL :&#xD;
&#xD;
               -  Induction failure, no CR after course 2 or MRD&gt;0,1% after 3 courses of high-risk&#xD;
                  protocol&#xD;
&#xD;
               -  early bone marrow or combined relapse of acute lymphoblastic leukaemia, no CR or&#xD;
                  MRD&gt;0,1% after 1 course 2-nd line therapy&#xD;
&#xD;
               -  ALL post ≥ 2nd relapse, no CR or MRD&gt;0,1% after 1 course 2-nd line therapy&#xD;
&#xD;
               -  Relapse or MRD &gt;0,1% of ALL after stem cell transplant (&gt; 60 days post alloHSCT)&#xD;
&#xD;
               -  Late bone marrow or combined relapse of acute lymphoblastic leukaemia, no CR or&#xD;
                  MRD&gt;0,1% after 2nd course of 2-nd line therapy&#xD;
&#xD;
          -  There must be no available alternative curative therapies&#xD;
&#xD;
          -  CD19 expression must be detected on greater than 30% by flow cytometry&#xD;
&#xD;
          -  Patients must have measurable or evaluable disease at the time of enrolment, which may&#xD;
             include any evidence of disease including minimal residual disease detected by flow&#xD;
             cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.&#xD;
&#xD;
          -  Patient Clinical Performance Status: Karnofsky &gt;50% or Lansky &gt;50%&#xD;
&#xD;
          -  Patient Life Expectancy &gt; 8 weeks&#xD;
&#xD;
          -  Patients recovered from acute toxic effects of all prior chemotherapy, immuno- or&#xD;
             radiotherapy&#xD;
&#xD;
          -  Patient absolute lymphocyte N &gt; or =100/mm3&#xD;
&#xD;
          -  Patient cardiac function: left ventricular ejection fraction greater than or equal to&#xD;
             40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by&#xD;
             ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO.&#xD;
&#xD;
          -  Patients who agree to long-term follow up for up to 5 years (if received CD19 CAR-T&#xD;
             cell infusion)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. &lt;30% expression of CD19 on the leukemic population&#xD;
&#xD;
          2. Active hepatitis B, C or HIV infection&#xD;
&#xD;
          3. Oxygen saturation &lt; or = 90%&#xD;
&#xD;
          4. Bilirubin &gt;3x upper norma limit&#xD;
&#xD;
          5. Creatinine &gt;3x upper norma limit&#xD;
&#xD;
          6. Active acute GVHD overall grade ≥2 (Seattle criteria)&#xD;
&#xD;
          7. Moderate/severe chronic GVHD (NIH consensus) requiring systemic steroids&#xD;
&#xD;
          8. Clinical signs of grade &gt;3 CNS disorders (seizure disorder, paresis, aphasia,&#xD;
             cerebrovascular, ischemia/hemorrhage, severe brain injuries, dementia, cerebellar&#xD;
             disease, organic brain syndrome, psychosis, coordination or movement disorder)&#xD;
&#xD;
          9. Pregnant or lactating women.&#xD;
&#xD;
         10. Active severe infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

